The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Abstract
OBJECTIVE: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. METHOD: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. RESULTS: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. CONCLUSIONS: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,987
Relation of sample size to the stability of component patterns.
Guadagnoli, E., & Velicer, W. F. (1988) · Psychological Bulletin · doi:10.1037/0033-2909.103.2.265 · Cited by 2,880
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Self-citationA Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Soumerai, S. B., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S., & Bollini, P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311006 · Cited by 480
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Neuropsychological Deficits in Schizophrenics: Relationship to Age, Chronicity, and Dementia
Heaton, R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950060033003 · Cited by 381
Harvey, P. D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R. C., Hoblyn, J., & Davis, K. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1080 · Cited by 338
Self-citationMeltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990) · Psychiatric Services · doi:10.1176/ps.41.8.892 · Cited by 338
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.197 · Cited by 310
The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.43 · Cited by 289
Cognitive functioning and positive and negative symptoms in schizophrenia
Addington, J., Addington, D., & Maticka-Tyndale, E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90039-t · Cited by 283
Buchanan, R. W., Holstein, C., & Breier, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Sample size calculations in studies of test accuracy
Obuchowski, N. A. (1998) · Statistical Methods in Medical Research · doi:10.1177/096228029800700405 · Cited by 221
Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1630 · Cited by 211
Effects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 196
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia
Casey, D. E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90029-q · Cited by 189
A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten, T. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200062009 · Cited by 188
Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00010-7 · Cited by 177
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Hoff, A. L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00242-6 · Cited by 133
Extrapyramidal Symptoms in Patients Treated With Risperidone
Simpson, G. M., & Lindenmayer, J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00010 · Cited by 132
Chouinard, G. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00007 · Cited by 124
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study
Rossi, A., Mancini, F., Stratta, P., et al. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00371.x · Cited by 120
Meyer‐Lindenberg, A., Gruppe, H., Bauer, U., Lis, S., Krieger, S., & Gallhofer, B. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979481 · Cited by 112
Kee, K. S., Kern, R. S., Marshall, B. D., & Green, M. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00026-7 · Cited by 110
Galletly, C. A., Clark, C. R., McFARLANE, A. C., & Weber, D. L. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00062-0 · Cited by 104
Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns
Breier, A. F., Buchanan, R. W., Irish, D., & Carpenter, W. T. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1249 · Cited by 104
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
Lindström, E., Eriksson, B., Hellgren, A., von Knorring, L., & Eberhard, G. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80105-7 · Cited by 103
Chouinard, G., & Albright, P. S. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00010 · Cited by 97
Risperidone versus Haloperidol on Secondary Memory: Can Newer Medications Aid Learning?
Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D. A., McGurk, S. R., Marder, S. R., & Mintz, J. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033375 · Cited by 93
Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D. A., McGurk, S. R., Marder, S. R., & Mintz, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00088-2 · Cited by 88
Albright, P. S., Livingstone, S. W., Keegan, D. L., Ingham, M., Shrikhande, S., & LeLorier, J. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199611050-00005 · Cited by 65
Grace, J., Bellus, S. B., Raulin, M. L., Herz, M. I., Priest, B., Brenner, V., Donnelly, K., Smith, P., & Gunn, S. (1996) · Psychiatric Services · doi:10.1176/ps.47.1.41 · Cited by 61
Cognitive impairment as a target for pharmacological treatment in schizophrenia
Davidson, M., & Keefe, R. S. E. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(95)00037-m · Cited by 59
Self-citationThe cost of cognitive impairment in schizophrenia
Sevy, S. M., & Davidson, M. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(95)00025-h · Cited by 56
Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction
Seidman, L. J., Pepple, J. R., Faraone, S. V., Kremen, W. S., Green, A. I., Brown, W. A., & Tsuang, M. T. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90095-u · Cited by 55
Sax, K. W., Strakowski, S. M., & Keck, P. E. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00067-x · Cited by 48
The effects of clozapine on cognitive functioning in treatment- resistant schizophrenic patients
Fujii, D. E. M., Ahmed, I., Jokumsen, M., & Compton, J. (1997) · Journal of Neuropsychiatry · doi:10.1176/jnp.9.2.240 · Cited by 47
The pharmacoeconomics of clozapine: a review.
Meltzer, H. Y., & Cola, P. A. (1994) · PubMed · Cited by 44
Recent Advances in the Pharmacotherapy of Schizophrenia
Borison, R. L. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030552 · Cited by 36
McGurk, S. R., Green, M. F., Wirshing, W. C., Ames, D., Marshall, B. D., Marder, S. R., & Mintz, J. (1997) · CNS Spectrums · doi:10.1017/s1092852900005058 · Cited by 26
Small sample longitudinal clinical trial with missing data: A comparison of analytic methods.
Delucchi, K., & Bostrom, A. (1999) · Psychological Methods · doi:10.1037/1082-989x.4.2.158 · Cited by 24
Citrome, L. (1997) · Postgraduate Medicine · doi:10.3810/pgm.1997.02.166 · Cited by 17
Cited by
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Self-citationClinical Practice Recommendations
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.4.163 · Cited by 995
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Metadata
- Authors
- Harvey, P. D., & Keefe, R. S. E.
- Venue
- American Journal of Psychiatry
- Published
- 2001-02-01
- Volume
- 158
- Issue
- 2
- Pages
- 176-184
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2128164348
- Cited by
- 620
- References
- 54
- FWCI
- 24.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.